Air Liquide today inaugurates its Paris Innovation Campus which includes the Tier One company’s largest R&D centre.
Located on the Plateau de Saclay, the fully renovated 15,000 square metre facility with 48 laboratories and pilot platforms illustrates Air Liquide’s open innovation approach, especially on the energy transition and environment, healthcare and digital transformation.
From 2019, the Innovation Campus will also host a deep-tech start-up accelerator. Not only will Air Liquide host start-ups but will grant them access to shared experimental facilities and customised support from Air Liquide experts, with the objective to accelerate the industrialisation of their offer.
With an investment of €50m, the facility is Air Liquide’s largest R&D centre, bringing together almost 500 people, including 350 researchers, as well as pilot platforms to design and test technologies at larger scale.
The centre is also a sustainable development innovation flagship as it is a high-performance energy building allowing to test new clean energies.
A fuel cell supplies part of the centre’s heating, cooling and electricity needs, using hydrogen generated in situ. The building is also equipped with 300 square metres of photovoltaic panels and supplied with 100% renewable energy sources (biomethane and electricity).
François Darchis, Senior Vice-President and member of the Air Liquide Group Executive Committee, supervising innovation, said, “Over the past five years, Air Liquide has reinvented its innovation approach, creating a global network of Innovation Campuses, in the United States (Delaware), in Asia (Shanghai, Tokyo) and in Europe (Paris, Frankfurt).”
“Each Campus includes an R&D Centre, working in close relation with Operations, and numerous partners, including universities and technology institutes, customers and start-ups. This open innovation strategy combines scientific expertise, capacity to develop technologies and digital solutions, to bring innovative offers to market more rapidly and to better serve our customers and patients.”